Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Fostamatinib for chronic immune thrombocytopenic purpura. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Idiopathic thrombocytopenic purpura (ITP) occurs when the immune system destroys platelets, which are cells in the blood that are necessary for normal blood clotting. Persons with the disease have too few platelets in the blood which causes bleeding. Adults tend to get a chronic (long-term) form of the disease.
Fostamatinib is a new drug for the treatment of ITP that is given as a tablet. Some studies have suggested fostamatinib may be helpful for people whose first treatment has failed and more studies are now aiming to show how well it works and that it is safe to use.
If fostamatinib is licenced for use in the UK, it could be a new treatment option for adults with chronic ITP that may cause fewer side effects than current treatments. Indexing Status Subject indexing assigned by CRD MeSH Chronic Disease; Humans; Oxazines; Purpura, Thrombocytopenic, Idiopathic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000677 Date abstract record published 11/05/2016 |